The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study
暂无分享,去创建一个
A. Lazzarin | O. Picconi | C. Mussini | P. Monini | F. Mazzotta | G. di Perri | S. Bellino | B. Ensoli | A. Tripiciano | F. Ensoli | A. Gori | C. Torti | M. Galli | G. Angarano | A. Cafaro | G. Tambussi | S. Nozza | A. Latini | G. Palamara | S. Bonora | E. Focà | L. Sighinolfi | C. Sgadari | N. Ladisa | O. Longo | V. Francavilla | G. Paniccia | V. Mercurio | M. D. Di Pietro | Angela Arancio | Giovanni Paniccia
[1] A. Lazzarin,et al. The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study , 2014, Retrovirology.
[2] M. Humbert,et al. Novel Biopanning Strategy To Identify Epitopes Associated with Vaccine Protection , 2013, Journal of Virology.
[3] R. Rappuoli,et al. HIV-1 Tat Promotes Integrin-Mediated HIV Transmission to Dendritic Cells by Binding Env Spikes and Competes Neutralization by Anti-HIV Antibodies , 2012, PloS one.
[4] A. Lazzarin,et al. Therapeutic Immunization with HIV-1 Tat Reduces Immune Activation and Loss of Regulatory T-Cells and Improves Immune Function in Subjects on HAART , 2010, PloS one.
[5] D. O’Connor,et al. Impact of Viral Dose and Major Histocompatibility Complex Class IB Haplotype on Viral Outcome in Mauritian Cynomolgus Monkeys Vaccinated with Tat upon Challenge with Simian/Human Immunodeficiency Virus SHIV89.6P , 2010, Journal of Virology.
[6] S. Arold,et al. Phosphatidylinositol‐(4,5)‐bisphosphate enables efficient secretion of HIV‐1 Tat by infected T‐cells , 2010, The EMBO journal.
[7] Susan Engelbrecht,et al. Functions of Tat: the versatile protein of human immunodeficiency virus type 1. , 2010, The Journal of general virology.
[8] M. Giacca,et al. Immobilized HIV‐1 Tat protein promotes gene transfer via a transactivation‐independent mechanism which requires binding of Tat to viral particles , 2009, The journal of gene medicine.
[9] M. Magnani,et al. HIV-1 Tat Addresses Dendritic Cells to Induce a Predominant Th1-Type Adaptive Immune Response That Appears Prevalent in the Asymptomatic Stage of Infection , 2009 .
[10] P. Narciso,et al. The therapeutic phase I trial of the recombinant native HIV-1 Tat protein , 2008, AIDS.
[11] D. Montefiori,et al. A Replication-Competent Adenovirus-Human Immunodeficiency Virus (Ad-HIV) tat and Ad-HIV env Priming/Tat and Envelope Protein Boosting Regimen Elicits Enhanced Protective Efficacy against Simian/Human Immunodeficiency Virus SHIV89.6P Challenge in Rhesus Macaques , 2007, Journal of Virology.
[12] M. Ciccozzi,et al. The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. , 2005, The Journal of infectious diseases.
[13] K. Khalili,et al. Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection. , 2003, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[14] Yuntao Wu,et al. Selective Transcription and Modulation of Resting T Cell Activity by Preintegrated HIV DNA , 2001, Science.
[15] M. Re,et al. Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients. , 2001, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[16] F. Mueller,et al. Antibody spectrum against the viral transactivator protein in patients with human immunodeficiency virus type 1 infection and Kaposi's sarcoma. , 2000, Journal of human virology.
[17] W. Blattner,et al. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. , 1998, Journal of human virology.
[18] Luigi Buonaguro,et al. HIV‐1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix‐associated heparan sulfate proteoglycans through its basic region , 1997, AIDS.
[19] A. Pardee,et al. Tat protein induces self-perpetuating permissivity for productive HIV-1 infection. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[20] J. Moore,et al. Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1 , 1997, Journal of virology.
[21] C. Van Lint,et al. Immune Hyperactivation of HIV-1-Infected T Cells Mediated by Tat and the CD28 Pathway , 1997, Science.
[22] M. Raffeld,et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma , 1994, Nature.
[23] P. Wingfield,et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation , 1993, Journal of virology.
[24] S. Salahuddin,et al. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients , 1990, Nature.
[25] C. Debouck,et al. Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV‐1 , 1990, Journal of medical virology.
[26] C. Debouck,et al. Natural antibodies to HIV‐tat epitopes and expression of HIV‐1 genes in vivo , 1988, Journal of medical virology.